Go to main content
R&D JW, leading global new drug development

Research Policy

Based on the long history and know-how in treatment and medicine field, the JW Holdings constantly researching and developing innovative new medicine. We are targeting the diseases with high demand for medical unmet needs, concentrating on the development of innovative new medicines using the JW’s unique technology, and conducting research activities in line with global trends through open innovation.
  • The WNT-pathway modulator in cancer therapy and tissue regeneration
  • The STAT3-specific inhibitor in cancer therapy and immune disease
  • The H4R-specific inhibitor in immune disease and ophthalmology
  • URAT1-specific inhibitor for metabolic and immune disease
  • Biomarker-based precision medicine
  • Development of big data platforms in chemo- and bio-informatics
  • Open innovation and application for new modalities
  • Controlled Release (SMEDDS, Multi-layered Coating)
  • Fixed-Dose Combination
  • Formulation Change
  • Process Development of NCE (Salt Selection, Polymorphism)
  • High Potency Drug (Peptide, Steroid)
  • High Value-added New Technology (High-quality Purification Technology, Continuous Flow Reaction)